MCID: ALL006
MIFTS: 56

Allergic Asthma

Categories: Immune diseases, Respiratory diseases

Aliases & Classifications for Allergic Asthma

MalaCards integrated aliases for Allergic Asthma:

Name: Allergic Asthma 12 25 15 71
Atopic Asthma 12 17
Extrinsic Asthma with Acute Exacerbation 12
Extrinsic Asthma with Status Asthmaticus 12
Atopic Asthma, Susceptibility to 6
Ige-Mediated Allergic Asthma 71
Extrinsic Asthma 25
Asthma Allergic 54

Classifications:



External Ids:

Disease Ontology 12 DOID:9415
ICD9CM 34 493.0
SNOMED-CT 67 389145006
ICD10 32 J45
UMLS 71 C0155877 C1827849

Summaries for Allergic Asthma

Genetics Home Reference : 25 Asthma is a breathing disorder characterized by inflammation of the airways and recurrent episodes of breathing difficulty. These episodes, sometimes referred to as asthma attacks, are triggered by irritation of the inflamed airways. In allergic asthma, the attacks occur when substances known as allergens are inhaled, causing an allergic reaction. Allergens are harmless substances that the body's immune system mistakenly reacts to as though they are harmful. Common allergens include pollen, dust, animal dander, and mold. The immune response leads to the symptoms of asthma. Allergic asthma is the most common form of the disorder. A hallmark of asthma is bronchial hyperresponsiveness, which means the airways are especially sensitive to irritants and respond excessively. Because of this hyperresponsiveness, attacks can be triggered by irritants other than allergens, such as physical activity, respiratory infections, or exposure to tobacco smoke, in people with allergic asthma. An asthma attack is characterized by tightening of the muscles around the airways (bronchoconstriction), which narrows the airway and makes breathing difficult. Additionally, the immune reaction can lead to swelling of the airways and overproduction of mucus. During an attack, an affected individual can experience chest tightness, wheezing, shortness of breath, and coughing. Over time, the muscles around the airways can become enlarged (hypertrophied), further narrowing the airways. Some people with allergic asthma have another allergic disorder, such as hay fever (allergic rhinitis) or food allergies. Asthma is sometimes part of a series of allergic disorders, referred to as the atopic march. Development of these conditions typically follows a pattern, beginning with eczema (atopic dermatitis), followed by food allergies, then hay fever, and finally asthma. However, not all individuals with asthma have progressed through the atopic march, and not all individuals with one allergic disease will develop others.

MalaCards based summary : Allergic Asthma, also known as atopic asthma, is related to ige responsiveness, atopic and aspergillosis, and has symptoms including wheezing, coughing and chest tightness. An important gene associated with Allergic Asthma is MS4A2 (Membrane Spanning 4-Domains A2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ciprofloxacin and Vancomycin have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and testes, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 An asthma that is characterized by symptoms that are triggered by an allergic reaction caused by inhaled allergens such as dust mite allergen, pet dander, pollen and mold. Allergic asthma is airway obstruction and inflammation that is partially reversible with medication. The disease has symptom coughing, has symptom wheezing, has symptom shortness of breath or has symptom rapid breathing, and has symptom chest tightness.

Related Diseases for Allergic Asthma

Diseases related to Allergic Asthma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 441)
# Related Disease Score Top Affiliating Genes
1 ige responsiveness, atopic 33.4 STAT6 RNASE3 MS4A2 IL5 IL4R IL4
2 aspergillosis 32.7 IL5 IL4 IL10 IFNG EPX CCL5
3 cytokine deficiency 31.6 IL9 IL5 IL13
4 urticaria 31.3 RNASE3 IL5 IL4 IL13 IL10
5 pollen allergy 31.3 RNASE3 IL5 IL4R IL13 EPX
6 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.2 IL17A IL10 IFNG
7 proteasome-associated autoinflammatory syndrome 1 31.1 RNASE3 IL5 IL4 IL17A IL13 IL10
8 toxocariasis 31.1 RNASE3 IL5 IL4 IL10
9 hypereosinophilic syndrome 31.0 RNASE3 IL9 IL5 IL4 IL13 IL10
10 eosinophilic pneumonia 31.0 RNASE3 IL5 IL4 IL13 CCL5 CCL17
11 intrinsic asthma 31.0 TSLP RNASE3 IL5 IL4 IL13 ADAM33
12 hepatitis a 30.9 IL4 IL10 IFNG
13 lung disease 30.9 RNASE3 IL9 IL5 IL4 IL17A IL13
14 chlamydia 30.8 IL5 IL4 IL17A IL10 IFNG
15 rhinitis 30.8 TSLP RNASE3 IL9 IL5 IL4R IL4
16 dermatitis 30.8 TSLP NPSR1 IL5 IL4 IL17A IL13
17 status asthmaticus 30.8 RNASE3 IL5 IL13 IL10 CCL5 CCL11
18 pulmonary eosinophilia 30.8 RNASE3 IL5 IL4 IL13 EPX CCL5
19 respiratory syncytial virus infectious disease 30.7 IL5 IL13 CCL5
20 autoimmune disease 30.7 IL9 IL5 IL4 IL17A IL13 IL10
21 vernal keratoconjunctivitis 30.7 RNASE3 IL5 IL4 IL13 CCL5 CCL11
22 chickenpox 30.7 IL4 IL10 IFNG
23 latex allergy 30.7 RNASE3 IL5 IL4 IL13
24 bronchitis 30.6 RNASE3 IL9 IL5 IL4 IL13 IL10
25 immune deficiency disease 30.6 IL4 IL13 IL10 IFNG CCL5
26 rubella 30.6 IL5 IL4 IL10 IFNG
27 chronic rhinitis 30.6 RNASE3 IL5 IL4 IL13 EPX
28 contact dermatitis 30.6 IL5 IL4 IL17A IL10 IFNG CCL17
29 allergic bronchopulmonary aspergillosis 30.5 IL5 IL4 IL10 IFNG EPX CCL17
30 conjunctivitis 30.5 RNASE3 IL5 IL4 IL13 IL10 IFNG
31 sarcoidosis 1 30.5 IL9 IL13 IFNG CCL5 CCL11
32 lymphopenia 30.5 ITK IL4 IL10 IFNG
33 ascaris lumbricoides infection 30.5 TSLP IL5 IL13 IL10 IFNG
34 ulcerative colitis 30.5 IL4 IL17A IL13 IL10 IFNG
35 colitis 30.5 IL4 IL17A IL13 IL10 IFNG
36 alopecia areata 30.5 IL4 IL17A IL13 IL10 IFNG
37 mycobacterium tuberculosis 1 30.5 IL4 IL17A IL10 IFNG
38 lichen planus 30.5 IL4 IL17A IL10 IFNG CCL5
39 hashimoto thyroiditis 30.5 IL5 IL4 IL17A IL10 IFNG
40 food allergy 30.4 STAT6 RNASE3 IL5 IL4R IL4 IL17A
41 parasitic protozoa infectious disease 30.4 IL5 IL4 IL17A IL13 IL10 IFNG
42 cellulitis 30.4 RNASE3 IL5 IL4 IL17A IL10 IFNG
43 celiac disease 1 30.4 IL5 IL4 IL17A IL13 IL10 IFNG
44 allergic conjunctivitis 30.4 RNASE3 IL5 IL4 IL13 IL10 IFNG
45 churg-strauss syndrome 30.3 RNASE3 IL5 IL17A IL10 CCL17 CCL11
46 arthritis 30.3 IL4 IL17A IL13 IL10 IFNG CCL5
47 allergic rhinitis 30.3 RNASE3 MS4A2 IL9 IL5 IL4R IL4
48 common variable immunodeficiency 30.3 IL5 IL4 IL10 IFNG
49 rheumatoid arthritis 30.3 NPSR1 IL4 IL17A IL13 IL10 IFNG
50 esophagitis 30.3 TSLP IL5 IL4 IL13 IL10 CCL5

Graphical network of the top 20 diseases related to Allergic Asthma:



Diseases related to Allergic Asthma

Symptoms & Phenotypes for Allergic Asthma

Symptoms:

12
  • wheezing
  • coughing
  • chest tightness
  • shortness of breath
  • rapid breathing

MGI Mouse Phenotypes related to Allergic Asthma:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.3 CCL11 CCL17 CCL5 EPX GATA3 IFNG
2 immune system MP:0005387 10.21 CCL11 CCL17 CCL5 EPX GATA3 IFNG
3 digestive/alimentary MP:0005381 10.13 GATA3 IFNG IL10 IL13 IL17A IL4
4 homeostasis/metabolism MP:0005376 10.13 EPX GATA3 IFNG IL10 IL13 IL17A
5 endocrine/exocrine gland MP:0005379 10.06 GATA3 IFNG IL10 IL13 IL17A IL4
6 integument MP:0010771 9.81 GATA3 IFNG IL10 IL13 IL17A IL4
7 no phenotypic analysis MP:0003012 9.5 ADAM33 GATA3 IFNG IL10 IL13 IL17A
8 respiratory system MP:0005388 9.36 CCL11 IFNG IL10 IL13 IL17A IL4

Drugs & Therapeutics for Allergic Asthma

Drugs for Allergic Asthma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 194)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
2
Vancomycin Approved Phase 4 1404-90-6 14969 441141
3
Metronidazole Approved Phase 4 443-48-1 4173
4
Budesonide Approved Phase 4 51333-22-3 63006 5281004
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Nitric Oxide Approved Phase 4 10102-43-9 145068
8
Cetirizine Approved Phase 4 83881-51-0 2678
9
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Ciclesonide Approved, Investigational Phase 4 141845-82-1, 126544-47-6 444033
12
Adenosine Approved, Investigational Phase 4 58-61-7 60961
13
Terbutaline Approved Phase 4 23031-25-6 5403
14
Norepinephrine Approved Phase 4 51-41-2 439260
15
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
16
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
17
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
18 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
19
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
20
Zafirlukast Approved, Investigational Phase 4 107753-78-6 5717
21
Theophylline Approved Phase 4 58-55-9 2153
22
Histamine Approved, Investigational Phase 4 51-45-6 774
23
Azelastine Approved Phase 4 58581-89-8 2267
24
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
25 Cytochrome P-450 Enzyme Inhibitors Phase 4
26 Complement C1 Inhibitor Protein Phase 4
27 Complement System Proteins Phase 4
28 Anti-Bacterial Agents Phase 4
29 Antiprotozoal Agents Phase 4
30 Antibiotics, Antitubercular Phase 4
31 Adrenergic beta-Agonists Phase 4
32 Adrenergic Agents Phase 4
33 Adrenergic Agonists Phase 4
34 Formoterol Fumarate Phase 4
35 Tocolytic Agents Phase 4
36 Adrenergic alpha-Agonists Phase 4
37 Vasoconstrictor Agents Phase 4
38 Epinephryl borate Phase 4
39 Mydriatics Phase 4
40 Antineoplastic Agents, Hormonal Phase 4
41 Acidophilus Phase 4
42
Beclomethasone Phase 4 4419-39-0 20469
43 Methylprednisolone Acetate Phase 4
44 Cholinergic Antagonists Phase 4
45 Antiviral Agents Phase 4
46
Histamine Phosphate Phase 4 51-74-1 65513
47 Histamine Antagonists Phase 4
48 Histamine H1 Antagonists, Non-Sedating Phase 4
49 Histamine H1 Antagonists Phase 4
50
Histidine Investigational, Nutraceutical Phase 4 71-00-1 6274

Interventional clinical trials:

(show top 50) (show all 352)
# Name Status NCT ID Phase Drugs
1 Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation After Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients Unknown status NCT03051698 Phase 4 C1-inhibitor;Antibiotics
2 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
3 mRNA Expression as a Biomarker of Xolair (Omalizumab) Response Unknown status NCT01584687 Phase 4
4 Assessment of Effectiveness and Safety of Annual Sublingual Immunotherapy in Children With Bronchial Asthma and/or Allergic Rhinitis Allergic to House Dust Mites Unknown status NCT01052610 Phase 4 sublingual house dust mites allergen extract;placebo in sublingual applicator
5 The Effect of Xolair (Omalizumab) on Inhibiting Leukotriene and Cytokine (IL-4 and IL-13) Release From Blood Basophils Completed NCT00657891 Phase 4 Omalizumab;Placebo
6 A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab)on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids Completed NCT00329381 Phase 4 Xolair;Xolair
7 A26-wk,Randomized,Dble-Blinded,Parallel-Grp,Placebo-Controlled,Multi-Centered Study to Eval.the Effect of Xolair(Omalizumab) on Improving the Tolerability of Spec.Immunotherapy in Patients With at Least Mod. Persistent Allergic Asthma Inadequately Controlled w/Inhaled Corticosteroids Completed NCT00691873 Phase 4 Placebo;Xolair
8 A 26-week, Randomized, Double-blind, Parallel-group, Placebo-controlled,Multi-center Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids Completed NCT00267202 Phase 4 Placebo;Omalizumab;Immunotherapy;Immunotherapy
9 A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID Completed NCT00296530 Phase 4 fluticasone propionate/salmeterol;fluticasone propionate;montelukast
10 A Proof Of Concept Study To Assess The Steroid Sparing Effect Of Combined Nasal And Inhaled Corticosteroid In Patients With Asthma And Persistent Rhinitis Completed NCT00903227 Phase 4 Fluticasone Evohaler pMDI;Placebo;Fluticasone Evohaler;Placebo intranasal spray;fluticasone propionate (Flixonase®)
11 Role of Montelukast in Asthma and Allergic Rhinitis Patients Completed NCT03380975 Phase 4 Montelukast 10mg
12 The Safety and Utility of Skin Testing With XOLAIR® (Omalizumab) and Placebo Omalizumab (Formulation Excipients) Completed NCT00777764 Phase 4 Cohort I;Cohort 2
13 A Compassionate Access Protocol to Assess the Safety of XolairTM (Omalizumab)in Patients (≥ 6 Years Old) With Severe Allergic Asthma Who Remain Symptomatic Despite Optimal Therapy Completed NCT00639691 Phase 4
14 Exhaled Breath Condensate and Nitric Oxide: Non-invasive Evaluation of Lung Disease After Treatment With Xolair Completed NCT00139152 Phase 4 Placebo;Xolair
15 A Randomized, Open Label, Parallel-group, International, Multicenter Study Evaluating Persistency of Response to Omalizumab During 32 Weeks Treatment Given as Add on to Optimized Asthma Therapy in Adult and Adolescent Patients With Severe Persistent Allergic Asthma, Who Remain Inadequately Controlled Despite GINA (2004) Step 4 Therapy Completed NCT00264849 Phase 4 Omalizumab
16 Multi-center, Open-label, Multiple Dose Study in Mild to Moderate Asthmatics (With IgE/Body Weight Combinations Above That in the SmPC Dosing Table) to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Omalizumab Completed NCT00546143 Phase 4 Omalizumab;Omalizumab;Omalizumab
17 Assessment of Bronchodilatory Effects of Cetirizine in Adults With Concomitant Allergic Rhinitis and Mild Asthma as Measured by Impulse Oscillometry. Completed NCT01781507 Phase 4 Cetirizine;Placebo
18 A 26-week Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Effect of Omalizumab on Markers of Asthma Impairment in Patients With Persistent Allergic Asthma Completed NCT00870584 Phase 4 Omalizumab;Placebo
19 Safety and Efficacy of Ultra-Rush High-Dose Sublingual Immunotherapy in Children With Asthma Allergic to Grass Pollen - Prospective, Randomized, Placebo Controlled Study. Completed NCT00518518 Phase 4 Staloral 300;placebo
20 A Prospective, Randomized, Double-Blind Study of the Efficacy of Omalizumab (Xolair) in Atopic Asthmatics With Good Lung Capacity Who Remain Difficult to Treat (EXACT) Completed NCT00096954 Phase 4 omalizumab (Xolair);placebo
21 A Randomized, Double-Blind Trial of the Effect of Different Anti-Asthmatic Treatments on Lung Function and on Exercise-Induced Bronchoconstriction in Children With Asthma Completed NCT00490243 Phase 4 budesonide and montelukast;budesonide and formoterol;montelukast;budesonide;placebo
22 Utility of Versican and Hyaluronan Measurement in Induced Sputum as Biomarker of Asthma Completed NCT00980707 Phase 4 Inhaled corticosteroid (fluticasone)
23 A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Trial to Explore the Effects of 78 Weeks Omalizumab Treatment Given as Add on Therapy on Markers of Airway Inflammation and Remodeling in Patients With Moderate to Severe Persistent Allergic Asthma Receiving Inhaled Corticosteroids and Long Acting Beta-agonists Completed NCT00670930 Phase 4 omalizumab at a dose of 0.016mg/kg/IU/mL;Placebo
24 A Randomised, Double-Blind Placebo-Controlled Study Assessing the Short-Term Effect of a Dermatophagoides Pteronyssinus Extract, Quantified in Mass Units, in Subjects With Perennial Mite Induced Asthma Completed NCT00492076 Phase 4
25 Efficacy of Lactbacillus GG on Wheeze and Allergic Sensitization in Infants at Risk Completed NCT00490425 Phase 4 Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)
26 Predicting the Clinical Response to Omalizumab With Anti-IgE Response or Syk Expression in Basophils Completed NCT02023151 Phase 4 Omalizumab
27 A Randomized, Open-label, Multicenter Study to Evaluate the Effect of Xolair (Omalizumab) as Add-on Therapy to Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing Compared to Isolated Inhaled Corticosteroid + Long-Acting Beta Agonist in Fixed or Flexible Dosing in the Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma Completed NCT00567476 Phase 4 Omalizumab;Inhaled corticosteroids (ICS);Long-acting beta 2-adrenergic agonist (LABA);Short-acting beta 2-adrenergic agonist (SABA)
28 Double Blind Placebo Controlled Study to Assess the Expression of IgE on Basophils and Dendritic Cells During Omalizumab Treatment. Completed NCT00454051 Phase 4 Omalizumab;placebo
29 A Phase IV, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Persistency of Response With or Without Xolair After Long-term Therapy (XPORT) Completed NCT01125748 Phase 4 Omalizumab;Placebo;Asthma therapies
30 A Description of Inflammatory Cell Types in Moderate to Severe Pediatric Asthma: Eosinophilic and Non Eosinophilic Sputum Markers While on Anti-IgE Therapy (Xolair) Completed NCT00283504 Phase 4 ANTI-IGE THERAPY (XOLAIR)
31 A Phase IV, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of the Efficacy of Omalizumab in Preventing Bronchoconstriction Following Environmental Cat Dander Exposure in Patients With Cat Dander-induced Asthma Completed NCT00495612 Phase 4 Omalizumab;Placebo
32 A Multi-centre, Open Label, Single Arm, 32-week Treatment Study in Subjects With Severe Eosinophilic Asthma Not Optimally Controlled With Current Omalizumab Treatment Who Are Switched From Omalizumab to Mepolizumab 100mg Subcutaneous (Study Number 204471- the OSMO Study) Completed NCT02654145 Phase 4 Mepolizumab 100mg SC;Albuterol/salbutamol MDIs;Omalizumab
33 Inner-City Anti-IgE Therapy for Asthma (ICAC-08) Completed NCT00377572 Phase 4
34 A Placebo Controlled, Double-Blind Investigation of the Therapeutic Utility of Xolair (Omalizumab) for Attenuating Aspirin Induced Bronchospasm in Patients With Aspirin Exacerbated Respiratory Disease (AERD) Undergoing Aspirin Desentization Completed NCT00555971 Phase 4 Omalizumab;placebo
35 The Effect of Omalizumab on Airway Responsiveness to Adenosine in Patients With Poorly Controlled Asthma Completed NCT00133042 Phase 4 omalizumab
36 Preventative Omalizumab or Step-up Therapy for Severe Fall Exacerbations (ICAC-20) Completed NCT01430403 Phase 4 Inhaled Corticosteroid Boost Therapy (ICS)
37 Efficacy Of Nebulised Beclometasone Versus Placebo In Preventing Viral Wheezing In Pre-School Children Completed NCT01265342 Phase 4 Beclomethasone;Placebo
38 A Study Evaluating the Effect of Omnaris Nasal Spray 200 mcg QD & Alvesco Inhalation Aerosol 80 BID vs Beconase AQ Nasal Spray 168 mcg BID & QVAR Inhalation Aerosol 40 mcg BID vs Placebo Nasal Spray QD & Placebo Inhalation Aerosol BID on Short Term Growth in Pediatric Subjects With Mild Asthma & Allergic Rhinitis Completed NCT01550471 Phase 4 Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo;Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase;QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo;QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris;Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase;Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris
39 Two Different Dosages of Nebulized Steroid Versus Parenteral Steroid in the Management of COPD Exacerbations Completed NCT01865500 Phase 4 Budesonide 4 mg;Budesonide 8 mg;Metil prednisolone
40 The Effect of Allergen Immunotherapy on Anti-viral Immunity in Patients With Allergic Asthma - A Randomized, Double-blind, Placebo-controlled Trial of HDM-AIT Recruiting NCT04100902 Phase 4 ODACTRA 12 SQ-HDM Sublingual Tablet;Placebo sublingual tablet
41 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Patients With Moderate to Severe Allergic Asthma Suspended NCT04195958 Phase 4 Omalizumab;Placebo
42 Proof of Concept Study to Assess Downstream Effects of Using Combined Intranasal Fluticasone Propionate Plus Azelastine Nasal Spray on Asthmatic Inflammation in Patients With Persistent Asthma and Allergic Rhinitis Terminated NCT02953106 Phase 4 Azelastine-Fluticasone Nasal;Placebos
43 A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma Withdrawn NCT00242359 Phase 4 omalizumab
44 Rationale for Therapy With Low Dose Steroids Combined With Long-acting beta2-agonists in Patients With Allergic Asthma: Redirecting Innate Immune Responses by Long-term Treatment With High Doses of Inhaled Steroids Withdrawn NCT00456313 Phase 4 FLIXOTIDE and SERETIDE
45 The Efficacy of Mepolizumab Treatment on Rhinovirus Induced Asthma Exacerbations Unknown status NCT01520051 Phase 3 Mepolizumab;Placebo
46 The Effect of a Humanised Monoclonal Anti-IgE Antibody,Omalizumab, on Disease Control and Bronchial Mucosal Inflammation in Non-atpic Asthma Unknown status NCT01113437 Phase 2, Phase 3 Omalizumab;Placebo
47 Efficacy and Safety of HCP1102 Capsule : A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Clinical Trial Completed NCT02552667 Phase 3 HCP1102+HGP0711Placebo;HCP1102Placebo+HGP0711
48 A Continued Access Protocol to Provide Xolair® (Omalizumab) to Subjects With Severe Allergic Asthma Who Have Received Xolair Treatment in a Previous Investigational Study Completed NCT00109200 Phase 3 Xolair (omalizumab)
49 A 1 Year, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Evaluation of Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Persistent, Inadequately Controlled Allergic Asthma Completed NCT00079937 Phase 3 Omalizumab;Placebo;Fluticasone
50 An Open-label Extension Study to Assess Long Term Safety and Tolerability of Omalizumab Treatment in Adults and Adolescents With Severe Allergic Asthma Who Participated in the 52 Week CIGE250011E2 Study Completed NCT00482248 Phase 3 Omalizumab

Search NIH Clinical Center for Allergic Asthma

Genetic Tests for Allergic Asthma

Anatomical Context for Allergic Asthma

MalaCards organs/tissues related to Allergic Asthma:

40
Lung, T Cells, Testes, Smooth Muscle, Skin, Neutrophil, Monocytes

Publications for Allergic Asthma

Articles related to Allergic Asthma:

(show top 50) (show all 8508)
# Title Authors PMID Year
1
Association between atopic asthma and a coding variant of Fc epsilon RI beta in a Japanese population. 6 61
8842731 1996
2
Association between nasal allergy and a coding variant of the Fc epsilon RI beta gene Glu237Gly in a Japanese population. 6
11702205 2001
3
A new variant of the beta subunit of the high-affinity receptor for immunoglobulin E (Fc epsilon RI-beta E237G): associations with measures of atopy and bronchial hyper-responsiveness. 6
8817330 1996
4
Thymic stromal lymphopoietin receptor-mediated IL-6 and CC/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1/2, p38, and JNK) and STAT3 pathways. 54 61
20483734 2010
5
Antibodies specific for a segment of human membrane IgE deplete IgE-producing B cells in humanized mice. 54 61
20458139 2010
6
Regulatory T cells in many flavors control asthma. 54 61
20164832 2010
7
IL-13 Gene Polymorphisms are Associated With Rhinosinusitis and Eosinophilic Inflammation in Aspirin Intolerant Asthma. 61 54
20358028 2010
8
Itk inhibitors: a patent review. 61 54
20218931 2010
9
Ligand-based molecular design of 4-benzylpiperidinealkylureas and amides as CCR3 antagonists. 54 61
19960358 2010
10
Potential role of interleukin-17 in the pathogenesis of bullous pemphigoid. 54 61
19945799 2010
11
Clinical characteristics according to sensitized allergens in adult korean patients with bronchial asthma. 54 61
20358023 2010
12
Allergic asthma in patients with common variable immunodeficiency. 61 54
19839975 2010
13
Functional polymorphism in CTLA4 gene influences the response to therapy with inhaled corticosteroids in Slovenian children with atopic asthma. 61 54
19895365 2010
14
TSLP directly impairs pulmonary Treg function: association with aberrant tolerogenic immunity in asthmatic airway. 54 61
20230634 2010
15
Effects of functional relaxation and guided imagery on IgE in dust-mite allergic adult asthmatics: a randomized, controlled clinical trial. 54 61
20145487 2010
16
Signal transduction by the atopy-associated human thymic stromal lymphopoietin (TSLP) receptor depends on Janus kinase function. 54 61
20128689 2010
17
RANTES gene polymorphisms and asthma risk: A meta-analysis. 61 54
20430255 2010
18
Activation of signal transducer and activator of transcription factor 1 by interleukins-13 and -4 in cultured human bronchial smooth muscle cells. 54 61
20093796 2009
19
Genetic associations with asthma and virus-induced wheezing: a systematic review. 61 54
20126925 2009
20
A low dose of Mycoplasma pneumoniae infection enhances an established allergic inflammation in mice: the role of the prostaglandin E2 pathway. 61 54
19552640 2009
21
Development of allergen-induced airway inflammation in the absence of T-bet regulation is dependent on IL-17. 61 54
19783683 2009
22
A thymic stromal lymphopoietin gene variant is associated with asthma and airway hyperresponsiveness. 61 54
19539984 2009
23
Expression of the high affinity IgE receptor by neutrophils of individuals with allergic asthma is both minimal and insensitive to regulation by serum IgE. 61 54
19359220 2009
24
Association of peroxisome proliferator-activated receptor-gamma gene polymorphisms with the development of asthma. 54 61
19217272 2009
25
Relationship between exhaled nitric oxide and IgE sensitisation in patients with asthma: influence of steroid treatment. 61 54
20298397 2009
26
Soluble human leucocyte antigen-G and interleukin-10 levels in isocyanate-induced asthma. 61 54
19302248 2009
27
Pulmonary suppressor of cytokine signaling-1 induced by IL-13 regulates allergic asthma phenotype. 61 54
19299500 2009
28
Effects of dermatophagoides pteronyssinus allergen-specific immunotherapy on the serum interleukin-13 and pulmonary functions in asthmatic children. 54 61
19493463 2009
29
N-acetyltransferase 2 (NAT2) polymorphism in patients with atopic asthma. 54 61
19608015 2009
30
Analyses of associations with asthma in four asthma population samples from Canada and Australia. 54 61
19247692 2009
31
T-box 21 transcription factor is responsible for distorted T(H)2 differentiation in human peripheral CD4+ T cells. 61 54
19348920 2009
32
A TLR2 polymorphism is associated with type 1 diabetes and allergic asthma. 54 61
19148143 2009
33
CD14 and toll-like receptor gene polymorphisms, country living, and asthma in adults. 54 61
19096003 2009
34
CD34+ hemopoietic progenitor cells are potent effectors of allergic inflammation. 54 61
19064280 2009
35
Are genes associated with energy metabolism important in asthma and BMI? 61 54
19191138 2009
36
Soluble interleukin-10 and transforming growth factor-beta in children with acute exacerbation of allergic asthma. 54 61
19191132 2009
37
Thymic stromal lymphopoietin overproduced by keratinocytes in mouse skin aggravates experimental asthma. 54 61
19188585 2009
38
Association analysis of TIM-1 -232G > A and 5383_5397 insertion/deletion polymorphisms with childhood asthma and total serum immunoglobulin E levels in middle China. 61 54
19476019 2009
39
ITK inhibitors in inflammation and immune-mediated disorders. 54 61
19689375 2009
40
Activation of peripheral Th17 lymphocytes in patients with asthma. 61 54
19811428 2009
41
Nerve growth factor localization in the nasal mucosa of patients with persistent allergic rhinitis. 54 61
19076929 2009
42
Changes in RANTES and beta-thromboglobulin after intensive exercise in patients with allergic asthma. 54 61
18716401 2009
43
Foxp3 expressing regulatory T-cells in allergic disease. 61 54
20429425 2009
44
IFN-gamma, IL-4 and IL-13 modulate responsiveness of human airway smooth muscle cells to IL-13. 61 54
19116009 2008
45
Association of HLA class II alleles with childhood asthma and Total IgE levels. 61 54
19052351 2008
46
Children with absent surfactant protein D in bronchoalveolar lavage have more frequently pneumonia. 54 61
18266831 2008
47
Association of ADAM33 gene polymorphisms with adult allergic asthma and rhinitis in a Chinese Han population. 54 61
18778489 2008
48
Identification of functional roles for both IL-17RB and IL-17RA in mediating IL-25-induced activities. 54 61
18768888 2008
49
Matrix metalloproteinase 8 contributes to solubilization of IL-13 receptor alpha2 in vivo. 54 61
18694590 2008
50
Filaggrin null mutations are associated with increased asthma exacerbations in children and young adults. 54 61
18307574 2008

Variations for Allergic Asthma

ClinVar genetic disease variations for Allergic Asthma:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MS4A2 NM_000139.5(MS4A2):c.710A>G (p.Glu237Gly)SNV risk factor 14807 rs569108 11:59863104-59863104 11:60095631-60095631

Expression for Allergic Asthma

Search GEO for disease gene expression data for Allergic Asthma.

Pathways for Allergic Asthma

Pathways related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.06 STAT6 RNASE3 MS4A2 ITK IL9 IL5
2
Show member pathways
13.85 STAT6 IL9 IL5 IL4R IL4 IL17A
3
Show member pathways
13.74 TSLP IL9 IL5 IL4R IL4 IL17A
4
Show member pathways
13.6 STAT6 IL9 IL5 IL4R IL4 IL17A
5
Show member pathways
13.45 STAT6 ITK IL9 IL5 IL4R IL4
6
Show member pathways
13.38 STAT6 IL9 IL5 IL4R IL4 IL17A
7
Show member pathways
13.37 IL9 IL5 IL4R IL4 IL17A IL13
8 12.87 STAT6 IL5 IL4R IL4 IL13 IFNG
9
Show member pathways
12.8 RNASE3 MS4A2 IL9 IL5 IL4 IL17A
10
Show member pathways
12.69 MS4A2 ITK IL4R IL4 IL10 IFNG
11
Show member pathways
12.69 ITK IL9 IL5 IL4 IL17A IL10
12 12.65 STAT6 ITK IL4 IL17A IL10 IFNG
13
Show member pathways
12.65 STAT6 IL5 IL4R IL4 IL17A IL13
14
Show member pathways
12.6 MS4A2 ITK IL5 IL4 IL13
15
Show member pathways
12.53 TSLP STAT6 IL9 IL5 IL4R IL4
16
Show member pathways
12.45 IL5 IL4 IL17A IL13 IFNG CCL17
17
Show member pathways
12.44 STAT6 IL4R IL4 GATA3 CCL11
18
Show member pathways
12.36 IL9 IL5 IL4 IL17A IL13 IL10
19
Show member pathways
12.31 IL10 CCL5 CCL17 CCL11
20
Show member pathways
12.17 STAT6 IL9 IL4R IL4
21 12.03 IL5 IL4 IL10 IFNG
22
Show member pathways
11.99 IL17A IL10 IFNG GATA3
23 11.93 IL5 IL4 IL13 IFNG GATA3
24 11.92 STAT6 IL4R IL4 IL17A IL13 IL10
25
Show member pathways
11.91 IL4R IL4 IL17A IFNG
26 11.86 IL5 IL4R IL4
27 11.83 IL17A IFNG CCL5
28
Show member pathways
11.83 IL5 IL4 IFNG GATA3
29 11.8 IL5 IL4 IL13 CCL5 CCL11
30 11.74 IL5 IL10 GATA3
31 11.71 STAT6 IL5 IL4R IL4 IL10 CCL17
32 11.62 IL4 IL13 IL10 CCL5
33 11.52 TSLP STAT6 CCL11
34 11.51 TSLP IL9 IL5 IL4 IL17A IL13
35 11.45 IL5 IL4R IL4 IFNG
36 11.37 IL5 IL4 IL13 IL10 IFNG
37 11.3 IL9 IL5 IL4 IL13 IL10 IFNG
38 11.26 TSLP IL9 IL5 IL4 IL17A IL13
39 11.12 STAT6 IL4R IL4 GATA3
40 11.11 IL9 IL5 IL4 IL17A IL13 IL10
41 11.03 STAT6 IL9 IL5 IL4R IL4 IL13
42 10.91 IL9 IL5 IL4R IL4 IL13

GO Terms for Allergic Asthma

Cellular components related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.8 TSLP RNASE3 IL9 IL5 IL4R IL4
2 extracellular space GO:0005615 9.47 TSLP RNASE3 IL9 IL5 IL4R IL4

Biological processes related to Allergic Asthma according to GeneCards Suite gene sharing:

(show all 41)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.1 TSLP STAT6 NPSR1 MS4A2 ITK IL5
2 positive regulation of cell proliferation GO:0008284 10.08 TSLP IL9 IL5 IL4 IFNG
3 cellular response to tumor necrosis factor GO:0071356 9.89 GATA3 CCL5 CCL17 CCL11
4 negative regulation of inflammatory response GO:0050728 9.88 IL4 IL13 IL10 GATA3
5 cellular response to interferon-gamma GO:0071346 9.86 CCL5 CCL17 CCL11
6 neutrophil chemotaxis GO:0030593 9.84 CCL5 CCL17 CCL11
7 chemokine-mediated signaling pathway GO:0070098 9.84 CCL5 CCL17 CCL11
8 response to virus GO:0009615 9.83 IFNG GATA3 CCL5 CCL11
9 positive regulation of cold-induced thermogenesis GO:0120162 9.81 STAT6 IL4R IL4 IL13
10 monocyte chemotaxis GO:0002548 9.8 CCL5 CCL17 CCL11
11 cellular response to interleukin-1 GO:0071347 9.8 IL17A CCL5 CCL17 CCL11
12 positive regulation of B cell proliferation GO:0030890 9.77 IL5 IL4 IL13
13 inflammatory response GO:0006954 9.76 MS4A2 IL9 IL5 IL17A IL13 CCL5
14 lymphocyte chemotaxis GO:0048247 9.75 CCL5 CCL17 CCL11
15 positive regulation of JAK-STAT cascade GO:0046427 9.72 IL5 IL10 CCL5
16 microglial cell activation GO:0001774 9.71 IL4 IL13 IFNG
17 positive regulation of chemokine biosynthetic process GO:0045080 9.68 IL4 IFNG
18 macrophage activation GO:0042116 9.68 IL4 IL13
19 positive regulation of interleukin-10 secretion GO:2001181 9.67 IL4 IL13
20 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.67 IL4 IL10
21 negative regulation of endothelial cell apoptotic process GO:2000352 9.67 IL4 IL13 IL10 GATA3
22 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.66 IL17A IFNG
23 positive regulation of interleukin-5 production GO:0032754 9.65 TSLP GATA3
24 positive regulation of immunoglobulin production GO:0002639 9.65 IL4R IL13
25 positive regulation of interleukin-5 secretion GO:2000664 9.65 TSLP GATA3
26 positive regulation of macrophage activation GO:0043032 9.65 IL4R IL13 IL10
27 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 TSLP IL4 IL13 IFNG CCL5
28 cytokine-mediated signaling pathway GO:0019221 9.65 STAT6 IL5 IL4R IL4 IL17A IL13
29 type 2 immune response GO:0042092 9.64 IL4 IL10
30 positive regulation of cellular respiration GO:1901857 9.64 IL4 IFNG
31 neuroinflammatory response GO:0150076 9.63 IL4 IFNG
32 positive regulation of interleukin-23 production GO:0032747 9.63 IL17A IFNG
33 positive regulation of mast cell degranulation GO:0043306 9.63 IL4R IL4 IL13
34 regulation of isotype switching GO:0045191 9.62 IL4 IL10
35 T-helper 2 cell differentiation GO:0045064 9.61 IL4 GATA3
36 interleukin-4-mediated signaling pathway GO:0035771 9.61 STAT6 IL4R
37 positive regulation of MHC class II biosynthetic process GO:0045348 9.61 IL4 IL10 IFNG
38 positive regulation of interleukin-13 production GO:0032736 9.58 TSLP IL4 GATA3
39 negative regulation of complement-dependent cytotoxicity GO:1903660 9.57 IL4 IL13
40 positive regulation of isotype switching to IgE isotypes GO:0048295 9.56 STAT6 IL4
41 immune response GO:0006955 9.4 MS4A2 IL9 IL5 IL4R IL4 IL17A

Molecular functions related to Allergic Asthma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.62 IL9 IL5 IL4 IL10
2 chemokine activity GO:0008009 9.54 CCL5 CCL17 CCL11
3 CCR chemokine receptor binding GO:0048020 9.43 CCL5 CCL17 CCL11
4 cytokine activity GO:0005125 9.36 TSLP IL9 IL5 IL4 IL17A IL13
5 cytokine receptor binding GO:0005126 9.33 IL9 IL4 IL13
6 CCR4 chemokine receptor binding GO:0031729 8.96 CCL5 CCL17

Sources for Allergic Asthma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....